IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
13th Nov 2006, 19:52 GMT
Today at the 70th Annual Meeting of the American College of Rheumatology, IBEX Technologies Inc. (TSX: IBT), an innovator in the development of diagnostics for the management of arthritis and cancer,...
IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis related news:
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis — Market Wire - Pharmaceuticals and Biotech
- Health Tip: Signs That You Have Kidney Stones — KLTV - Med Team
- Health Tip: Signs That You Have Kidney Stones (HealthDay) — Yahoo! Health: Health News
- Topspin begins preclinical testing of prostate cancer MRI — News
- ACR: Botox Is New Wrinkle In Osteoarthritis — MedPage Today Rheumatology
- Botox May Cut Knee Osteoarthritis Pain — WebMD Health Headlines
- A Difference In Leg Lengths Could Indicate Pattern For Osteoarthritis — Health News from Medical News Today
- One In Four Will Develop Symptomatic Hip Osteoarthritis By Age 85 — Health News from Medical News Today
- ACR: Small Weight Loss Equals Big Gains In Osteoarthritis Quality Of Life — MedPage Today.com Latest Headlines
- Cambridge get taste of Stour defeat instead of home help — CEN : Sports News
Latest news from ArriveNet : Health:
- Gold Reserve announces improved Brisas Project economics and updates Brisas Project 43-101 Report
- PuriCore Plc announces Appointment
- Lisa Zuckerman Joins Catholic Healthcare West as Vice President of Treasury Services
- ORLive Presents: Minimally Invasive Aortic Valve Replacement Surgery -- Increasingly Popular Procedure to Correct Heart Function
- Adult Stem Cells Have Ability to Develop and Replicate Like Embryonic Stem Cells
- Extraordinary general meeting of Precise Biometrics AB approves of new share issue with preferential rights for shareholders of approximately SEK 85 million
- Invitation Conference Call Analyst Meeting
- YES Secures 100 Country Distribution Deal, Announces First Int'l Shipments Begin
- Lenstec Receives FDA Clearance to Begin Clinical Trial of Softec HD IOL
- Study to Be Published in JAMA: Diabetes Drug ACTOS(R) (pioglitazone HCl) Halted Progression of Key Marker for Atherosclerosis; Improvements Indicated by Carotid Intima-Media Thickness (CIMT)